Cite
HARVARD Citation
Derfuss, T. et al. (n.d.). P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Clinical neurophysiology. 131 (4), pp. e196-. [Online].